These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 8261412

  • 1. Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities.
    Riou JF, Fossé P, Nguyen CH, Larsen AK, Bissery MC, Grondard L, Saucier JM, Bisagni E, Lavelle F.
    Cancer Res; 1993 Dec 15; 53(24):5987-93. PubMed ID: 8261412
    [Abstract] [Full Text] [Related]

  • 2. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
    Poddevin B, Riou JF, Lavelle F, Pommier Y.
    Mol Pharmacol; 1993 Oct 15; 44(4):767-74. PubMed ID: 8232227
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Further SAR in the new antitumor 1-amino-substituted gamma-carbolines and 5H-benzo[e]pyrido[4,3-b]indoles series.
    Nguyen CH, Lavelle F, Riou JF, Bissery MC, Huel C, Bisagni E.
    Anticancer Drug Des; 1992 Jun 15; 7(3):235-51. PubMed ID: 1319166
    [Abstract] [Full Text] [Related]

  • 5. Novel antitumor indenoindole derivatives targeting DNA and topoisomerase II.
    Bal C, Baldeyrou B, Moz F, Lansiaux A, Colson P, Kraus-Berthier L, Léonce S, Pierré A, Boussard MF, Rousseau A, Wierzbicki M, Bailly C.
    Biochem Pharmacol; 2004 Nov 15; 68(10):1911-22. PubMed ID: 15476662
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin.
    Bailly C, Riou JF, Colson P, Houssier C, Rodrigues-Pereira E, Prudhomme M.
    Biochemistry; 1997 Apr 01; 36(13):3917-29. PubMed ID: 9092822
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Rational design and molecular effects of a new topoisomerase II inhibitor, azatoxin.
    Leteurtre F, Madalengoitia J, Orr A, Guzi TJ, Lehnert E, Macdonald T, Pommier Y.
    Cancer Res; 1992 Aug 15; 52(16):4478-83. PubMed ID: 1322792
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives.
    Tanabe K, Ikegami Y, Ishida R, Andoh T.
    Cancer Res; 1991 Sep 15; 51(18):4903-8. PubMed ID: 1654204
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Synthesis, properties and biological evaluation of substituted furo[3,2-e] and pyrano[3,2-e]pyrido[4,3-b]indoles.
    Costache E, Nguyen CH, Guilbaud N, Léonce S, Pierré A, Atassi G, Bisagni E.
    Anticancer Drug Des; 1998 Jun 15; 13(4):373-86. PubMed ID: 9627674
    [Abstract] [Full Text] [Related]

  • 15. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity.
    Jaxel C, Kohn KW, Wani MC, Wall ME, Pommier Y.
    Cancer Res; 1989 Mar 15; 49(6):1465-9. PubMed ID: 2538227
    [Abstract] [Full Text] [Related]

  • 16. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities.
    Bailly C, Qu X, Chaires JB, Colson P, Houssier C, Ohkubo M, Nishimura S, Yoshinari T.
    J Med Chem; 1999 Jul 29; 42(15):2927-35. PubMed ID: 10425102
    [Abstract] [Full Text] [Related]

  • 17. Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl pyridines.
    Karki R, Thapa P, Kang MJ, Jeong TC, Nam JM, Kim HL, Na Y, Cho WJ, Kwon Y, Lee ES.
    Bioorg Med Chem; 2010 May 01; 18(9):3066-77. PubMed ID: 20392646
    [Abstract] [Full Text] [Related]

  • 18. Activity of intoplicine (RP60475), a new DNA topoisomerase I and II inhibitor, against human tumor colony-forming units in vitro.
    Eckardt JR, Burris HA, Kuhn JG, Bissery MC, Klink-Alakl M, Clark GM, Von Hoff DD.
    J Natl Cancer Inst; 1994 Jan 05; 86(1):30-3. PubMed ID: 8271279
    [Abstract] [Full Text] [Related]

  • 19. Syntheses and biological evaluation of indolocarbazoles, analogues of rebeccamycin, modified at the imide heterocycle.
    Moreau P, Anizon F, Sancelme M, Prudhomme M, Bailly C, Carrasco C, Ollier M, Sevère D, Riou JF, Fabbro D, Meyer T, Aubertin AM.
    J Med Chem; 1998 May 07; 41(10):1631-40. PubMed ID: 9572888
    [Abstract] [Full Text] [Related]

  • 20. Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II.
    Wassermann K, Markovits J, Jaxel C, Capranico G, Kohn KW, Pommier Y.
    Mol Pharmacol; 1990 Jul 07; 38(1):38-45. PubMed ID: 2164630
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.